J Korean Acad Rehabil Med.  2001 Jun;25(3):431-437.

Selective Removal of Fibroblast with Using Proline Analogue and Cytosine Arabinoside in Myoblast Culture

Affiliations
  • 1Department of Rehabilitation Medicine, Yonsei University College of Medicine.
  • 2Department of Rehabilitation Institute of Muscular Disease, Yonsei University College of Medicine.

Abstract


OBJECTIVE
The phenomenon of fibroblast overgrowth is one of the major problems encountered during long-term culture such as myoblast culture. The first goal of the study is to determine the effects of proline analogue and cytosine arabinoside to reduce fibroblasts in myoblast culture. The second goal is to investigate whether the chemicals influence the growth and differentiation of myoblast. METHOD: Muscle tissues were obtained from legs of healthy men, and then fibroblasts and myoblasts were isolated and cultured. Those mixed cells were divided into three groups; control group, proline analogue (cis-hydroxyproline) treated group and cytosine arabinoside (araC) treated group. We evaluated the effectiveness of cis-hydroxyproline and araC on selective removal of fibroblasts in culture. We have also determined if cis-hydroxyproline and araC could alter differentiation of myoblast in each group.
RESULTS
The treatment with araC was effective to eliminate fibroblasts comparing to the control group (p<0.05) while there was no statistically significant difference between proline analogue and control group (p>0.05). Myoblasts of all three groups were differentiated into myotube.
CONCLUSION
Using araC, we could reduce a number of fibroblasts in myoblast culture where contamination and subsequent overgrowth with fibroblasts remained a problem.

Keyword

Myoblast; Fibroblast; Proline analogue; Cytosine arabinoside

MeSH Terms

Cytarabine*
Cytosine*
Fibroblasts*
Humans
Leg
Male
Muscle Fibers, Skeletal
Myoblasts*
Proline*
Cytarabine
Cytosine
Proline
Full Text Links
  • JKARM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr